Photo taken from Dana-Farber’s Breast Oncology Center/X
May 15, 2024, 13:18
Our newest treatment guideline on the use of low-dose Tamoxifen in ER+ DCIS – Dana-Farber’s Breast Oncology Center
Dana-Farber’s Breast Oncology Center shared on X:
“Check out our newest treatment guideline on the use of low-dose tamoxifen in patients with estrogen receptor-positive (ER+) ductal carcinoma in situ (DCIS).”
Additional information.
Source: Dana-Farber’s Breast Oncology Center/X